Back

Real-world off-label Sacubitril/Valsartan dosing and clinical outcomes in patients with heart failure and end-stage kidney disease

31 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Real-world cardiorenal therapeutics: outcomes and mechanisms in advanced kidney disease Renal Failure and Cardiovascular Disease ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Sung Il Im

kosin university gospel hospital, Pusan (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail
Impact of cumulative contrast volume on medium- to long-term renal function in patients undergoing repeated percutaneous coronary interventions
Doctor P. Steinhoff (Bad Krozingen, DE)
Abstract Slides Video
Presentation thumbnail
Incidence and predictors of echocardiographic cardiac deterioration after arteriovenous access surgery
Doctor L. Fisher (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
Longitudinal change in epicardial adipose tissue attenuation on serial non-contrast chest CT in finerenone-treated patients: a real-world cohort study
Doctor X. Zhang (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
CV inflammation prevalence and clinical biomarkers (hsCRP, IL-6 and NT-proBNP) levels in adults with ASCVD and CKD in KSA and UAE: Insights from the INFLAMEAST real‑world study
Doctor M. Alasnag (Jeddah, SA)
Abstract Slides Video
Presentation thumbnail
Glp-1 receptor agonists and cardiovascular outcomes in obese patients on dialysis:insights –from the TriNetX real-world database
Mrs B. Prado (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Real-world cardiorenal therapeutics: outcomes and mechanisms in advanced kidney disease

The Event

Event poster

ESC Congress 2026

31 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Real world data using sacubitril/valsartan in CKD stage 4 and 5 is associated with improved ejection fraction and may have renoprotective effects.
12 May 2024
thumbnail
Congress Presentation
Impact of real-world off-label dose of apixaban on long-term clinical outcomes in heart failure patients with atrial fibrillation and end stage kidney disease
31 August 2025
thumbnail
Congress Presentation
Management of heart failure and health service planning in chronic kidney disease
29 August 2026
thumbnail
Congress Presentation
Efficacy of sacubitril/valsartan on mortality in asymptomatic hypotensive HFrEF: data from the China Cardiovascular Association Database-Heart Failure Center Registry
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources